Stereotaxis Q3 revenue $7.8M (+1% YoY); net loss $5.4M; cash $23M, no debt

Stereotaxis, Inc.

2023-Q3 EPS reported -$0.21 revenue$22,206,000

System revenue $3.5M from 2 Genesis systems; recurring revenue $4.3M (down 19% YoY, lost catheter royalties).
Gross margin 52%; operating loss $5.6M vs $5.1M a year ago; adjusted operating loss $3.0M.
Cash and equivalents $23.0M at Sept 30, 2023; no debt; negative free cash flow $1.0M in Q3.
Expects to submit PMA supplement for MAGiC ablation catheter before year-end.
System backlog $13M; expects continued revenue growth in coming quarters.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Stereotaxis, Inc. reported the third quarter ended September 30, 2023 results: revenue $7.8 million, net income ($5.4) million.

Period: the third quarter ended September 30, 2023
Revenue: $7.8 million
Net income: ($5.4) million
Result: reported results

Exact text from the filing

Revenue for the third quarter of 2023 totaled $7.8 million, compared to $7.7 million in the prior year third quarter.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Stereotaxis, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.